<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290589</url>
  </required_header>
  <id_info>
    <org_study_id>03-05-107</org_study_id>
    <nct_id>NCT00290589</nct_id>
  </id_info>
  <brief_title>A Trial of Corticosteroids for Low Back Pain</brief_title>
  <official_title>Utility of Intramuscular Corticosteroids for Radicular Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain is a common symptom that functionally disables many people. When the low back
      pain is accompanied by pain that shoots down the leg, it is felt to be caused by a herniated
      disc. We are conducting this study to determine if a powerful anti-inflammatory agent will
      decrease the pain and functional impairment that is associated with this illness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind placebo-controlled clinical trial evaluating intramuscular
      methylprednisolone acetate as adjunctive therapy for radicular low back pain. This trial
      randomizes subjects after they had been evaluated and treated in the ED and are ready for
      discharge. All subjects are followed by telephone call one week and one month after ED
      discharge. In addition to the steroid injection, all subjects are given a complimentary one
      week supply of naproxen 500 mg tablets and oxycodone 5mg/ acetaminophen 325 tablets and a
      detailed low back pain instruction sheet. This study was approved by the Montefiore Medical
      Center institutional review board.

      Patients are included if their low back pain lasted less than one week, if they are 50 years
      old or younger, and if they had not experienced any direct trauma to the back during the
      previous week. Low back pain is described as pain originating below the tips of the scapulae
      and above the buttocks.Patients are only included if their straight leg raise test, as
      described below, is positive. Patients are excluded if the emergency physician felt that
      there is a high likelihood that the patient has a secondary cause of low back pain, e.g.,
      metastatic bone disease or infection. Patients are also excluded for temperature greater than
      100.3 degrees, pregnancy, lactation, allergy to or intolerance of a study medication.
      Patients can only enroll once. Patients can not have had another episode of back pain within
      four weeks prior to the current back pain attack. Patients are excluded for systemic steroid
      use within four weeks, a history of back surgery, a neoplasia known to metastasize, a chronic
      pain syndrome, an inflammatory arthritis, suspected vascular, urologic or gynecologic
      pathology, or direct blunt trauma to the back within the previous week.

      Rationale for the straight leg raise test: Although the true test characteristics of the
      straight leg raise test are unknown, a positive ipsilateral straight leg raise is felt to be
      a sensitive marker for a herniated intervertebral disc. Therefore, if this test is negative,
      it can help rule-out the disease. To maintain a homogenous cohort, subjects were stratified
      based on results of the straight leg raise test. Many definitions of the straight leg raise
      test exist. In order to identify distinct populations, the research assistants were given a
      strictly-defined, conservative definition of this test: namely, the test was considered
      positive if a subject had ipsilateral pain shooting below the knee when either leg was raised
      between 30 and 70 degrees, as measured with a protractor. Contralateral pain below the knee,
      considered more specific for a herniated disc, was also considered a positive straight leg
      raising test.

      All patients with low back pain are treated at the discretion of the attending physician.
      When the patient's pain had been controlled to a level sufficient for the patient to be
      discharged, the patient is asked for consent to participate as a research subject. After
      consent is obtained, subjects receive an intramuscular injection of methylprednisolone
      acetate or placebo. All subjects are discharged with a &quot;back pack&quot; containing 14 tablets of
      naproxen 500mg, 12 tablets of oxycodone 5mg/ acetaminophen 325 tablets, and a standardized
      discharge instruction sheet.

      Subjects are followed-up by telephone at one week and one month after discharge. At each of
      these telephone interviews, research assistants read standardized questions about pain and
      activity limitations from the data collection instrument.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable</measure>
    <time_frame>1 month</time_frame>
    <description>Improvement in Numerical Rating Scale between the time of the emergency department visit and the one month telephone call is rated on an 11-point scale ranging from 0-10 with 0 indicating no pain and 10 indicating worse pain imaginable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Disability Scales</measure>
    <time_frame>1 month</time_frame>
    <description>The low back pain functional disability scale is the Roland Morris Disability questionnaire score (RMDQ). The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Using Analgesics</measure>
    <time_frame>Assessed at 1 month</time_frame>
    <description>Use of analgesics for low back pain (within the previous 24 hours)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Radicular Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Intramuscular methylprednisolone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone acetate 160mg intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular methylprednisolone acetate</intervention_name>
    <description>Intramuscular methylprednisolone acetate 160mg</description>
    <arm_group_label>Intramuscular methylprednisolone acetate</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-50 years old, non-traumatic low back pain for one week or less,

        Exclusion Criteria:

          -  fever, pregnancy, lactation, allergy or intolerance to study medication, suspected
             active oncologic, urologic, or gynecologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Friedman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 9, 2006</study_first_submitted>
  <study_first_submitted_qc>February 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>April 20, 2018</results_first_submitted>
  <results_first_submitted_qc>August 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 7, 2019</results_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Prof. Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>low back pain</keyword>
  <keyword>emergency department</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intramuscular Methylprednisolone Acetate</title>
          <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intramuscular Methylprednisolone Acetate</title>
          <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="9"/>
                    <measurement group_id="B2" value="37" spread="8"/>
                    <measurement group_id="B3" value="38" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Back Pain Prior to Study</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="B2" value="48" lower_limit="14" upper_limit="72"/>
                    <measurement group_id="B3" value="48" lower_limit="24" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable</title>
        <description>Improvement in Numerical Rating Scale between the time of the emergency department visit and the one month telephone call is rated on an 11-point scale ranging from 0-10 with 0 indicating no pain and 10 indicating worse pain imaginable.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Methylprednisolone Acetate</title>
            <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (0-10), an Interval Pain Scale, on Which 0 Indicates no Pain and 10 Indicates the Worst Pain Imaginable</title>
          <description>Improvement in Numerical Rating Scale between the time of the emergency department visit and the one month telephone call is rated on an 11-point scale ranging from 0-10 with 0 indicating no pain and 10 indicating worse pain imaginable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="3.0"/>
                    <measurement group_id="O2" value="5.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional Disability Scales</title>
        <description>The low back pain functional disability scale is the Roland Morris Disability questionnaire score (RMDQ). The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Methylprednisolone Acetate</title>
            <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Disability Scales</title>
          <description>The low back pain functional disability scale is the Roland Morris Disability questionnaire score (RMDQ). The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Using Analgesics</title>
        <description>Use of analgesics for low back pain (within the previous 24 hours)</description>
        <time_frame>Assessed at 1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramuscular Methylprednisolone Acetate</title>
            <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Using Analgesics</title>
          <description>Use of analgesics for low back pain (within the previous 24 hours)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intramuscular Methylprednisolone Acetate</title>
          <description>Methylprednisolone acetate 160mg intramuscular injection
intramuscular methylprednisolone acetate: Intramuscular methylprednisolone acetate 160mg</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo intramuscular injection
Placebo: Normal saline intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="43" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bloating (Gastrointestinal)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="43" subjects_affected="5" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin W. Friedman, MD, MS</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>(718)920-6266</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

